嵌合抗原受体
生物
成纤维细胞活化蛋白
细胞毒性T细胞
癌症研究
间质细胞
过继性细胞移植
抗原
T细胞
CD8型
免疫学
免疫系统
癌症
体外
生物化学
遗传学
作者
Liang‐Chuan S. Wang,Albert Lo,John Scholler,Jing Sun,Rajrupa S. Majumdar,Veena Kapoor,Michael Antzis,Cody E. Cotner,Laura A. Johnson,Amy C. Durham,Charalambos Solomides,Carl H. June,Ellen Puré,Steven Μ. Albelda
标识
DOI:10.1158/2326-6066.cir-13-0027
摘要
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages. We developed a retroviral CAR construct specific for the mouse fibroblast activation protein (FAP), comprising a single-chain Fv FAP [monoclonal antibody (mAb) 73.3] with the CD8α hinge and transmembrane regions, and the human CD3ζ and 4-1BB activation domains. The transduced muFAP-CAR mouse T cells secreted IFN-γ and killed FAP-expressing 3T3 target cells specifically. Adoptively transferred 73.3-FAP-CAR mouse T cells selectively reduced FAP(hi) stromal cells and inhibited the growth of multiple types of subcutaneously transplanted tumors in wild-type, but not FAP-null immune-competent syngeneic mice. The antitumor effects could be augmented by multiple injections of the CAR T cells, by using CAR T cells with a deficiency in diacylglycerol kinase, or by combination with a vaccine. A major mechanism of action of the muFAP-CAR T cells was the augmentation of the endogenous CD8(+) T-cell antitumor responses. Off-tumor toxicity in our models was minimal following muFAP-CAR T-cell therapy. In summary, inhibiting tumor growth by targeting tumor stroma with adoptively transferred CAR T cells directed to FAP can be safe and effective, suggesting that further clinical development of anti-human FAP-CAR is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI